Drug profile · INN
sulindac
SULINDAC
sulindac (SULINDAC) is a cyclooxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 1
Pipeline programs 0
News articles 0
Drug details — sulindac
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 0
- Data quality
- 0.84
Quick answer
sulindac (SULINDAC) is a cyclooxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN sulindac
Brand SULINDAC
Mechanism Cyclooxygenase inhibitor
Target Cyclooxygenase
Route ORAL
Formulation TABLET
Mechanism of action
Cyclooxygenase inhibitor
Primary target: Cyclooxygenase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is sulindac?
sulindac (SULINDAC) is a cyclooxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sulindac?
SULINDAC is a marketed brand name for sulindac. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sulindac?
sulindac has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.